1-5 of 5
Martha Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Youn H. Kim, MD, H. Miles Prince, MD FRACP, FRCPA, Sean Whittaker, MB, ChB, FRCP, MD, Steven M. Horwitz, MD, Madeleine Duvic, MD, Oliver Bechter, Jose A. Sanches, Rudolf Stadler, MD, Julia Scarisbrick, MD FRCP, MBBS, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Lauren C. Pinter-Brown, MD, Pablo L. Ortiz-Romero, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, Michael Weichenthal, MD, Jan Walewski, MD, David C. Fisher, MD PhD, Marise McNeeley, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Julie Lisano, Martha Li, Hui-Min Lin, PhD, Meredith Little, MPH, William L. Trepicchio, PhD, Reinhard Dummer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2018-99-112847
Published: 2018
Journal Articles

Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Christopher A. Yasenchak, MD, Ahmad Halwani, MD, Ranjana Advani, Stephen Ansell, MD PhD, Lihua Elizabeth Budde, MD PhD, John M. Burke, MD, Charles M. Farber, MD PhD, Beata Holkova, MD, Luis E. Fayad, MD, Kathryn S. Kolibaba, MD, Mark Knapp, MD, Martha Li, PhD, Thomas J. Manley, MD, Dipti Patel-Donnelly, MD, Mahesh Seetharam, MD, Habte A. Yimer, MD, Nancy L Bartlett, MD
Journal: Blood
Blood (2015) 126 (23): 814.
https://doi.org/10.1182/blood.V126.23.814.814
Published: 2015
Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

Jeffrey Lee Wolf, David Siegel, Jeffrey Matous, Sagar Lonial, Hartmut Goldschmidt, Stefan Schmitt, Ravi Vij, Margarida De Malgalhaes-Silverman, Rafat Abonour, Muhammad Jalaluddin, Martha Li, Katharine Hazell, Priscille M. Bourquelot, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Spencer, Jean-Luc Harousseau, Joan Bladé
Journal: Blood
Blood (2008) 112 (11): 2774.
https://doi.org/10.1182/blood.V112.11.2774.2774
Published: 2008
Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

Andrey Zaritskey, Giuliana Alimena, Lech Konopka, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Anna Turkina, Gert J. Ossenkoppele, Stuart L. Goldberg, Bayard Powell
Journal: Blood
Blood (2008) 112 (11): 4254.
https://doi.org/10.1182/blood.V112.11.4254.4254
Published: 2008
Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

François Guilhot, Viviane Dubruille, Aleksander B. Skotnicki, Andrey Hellmann, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Elisabetta Abruzzese, Luke Akard
Journal: Blood
Blood (2008) 112 (11): 4263.
https://doi.org/10.1182/blood.V112.11.4263.4263
Published: 2008